Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy
Andrew J. Roth
Advertisement
Articles by Andrew J. Roth
The chimeric antigen receptor T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
Advertisement
Latest Updated Articles
June Provides Insight Into Managing AEs From CAR T-Cell TherapiesPublished: November 21st 2015 | Updated:
CAR T-Cell Therapy Surpasses 90% Complete Remission Rate in Pediatric ALLPublished: April 24th 2015 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – November 26, 2025
2
FDA Approves Itvisma, a New Intrathecal Route for Novartis’ SMA Gene Therapy
3
Guess the Therapy Answer November 26, 2025
4
Sarepta's Elevidys Gets Boxed Warning for ALI and ALF
5
